Study to Evaluate the Effects of a Formula on the Gut Health of Healthy Chinese Infants and Young Children

Sponsor
Danone Nutricia (Industry)
Overall Status
Recruiting
CT.gov ID
NCT04864665
Collaborator
Nutricia Early Life Nutrition (Shanghai) Co., Ltd (Other)
495
6
1
22
82.5
3.8

Study Details

Study Description

Brief Summary

The infant gut microbiota, a major driver of the maturation of the immune system, is formed through the successive establishment and development during infancy and early childhood. It can inhibit the growth of pathogenic bacteria, prevent the occurrence of diseases and improve the child's quality of life. It is therefore important to regulate the microbiota balance in infants and young children.

This objective of this post-launch study is to evaluate the effects of a formula with prebiotics and milk fat on the gut microbiota and stool characteristics of healthy Chinese infants and young children. The duration of the study for each participant is 32 days and includes 3 study visits.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: a formula with prebiotics and milk fat
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
495 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
interventional with breastfed reference groupinterventional with breastfed reference group
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
A Prospective, Multicentre Before and After Study to Evaluate the Effects of a Formula With Prebiotics and Milk Fat, on the Gut Health of Chinese Infants and Young Children
Actual Study Start Date :
May 11, 2021
Anticipated Primary Completion Date :
Dec 15, 2022
Anticipated Study Completion Date :
Mar 11, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Formula fed

0 - 6 months: a formula with prebiotics and milk fat (Stage 1); >6 - 12 months: a formula with prebiotics and milk fat (Stage 2); >1 - 2 years: a formula with prebiotics and milk fat (Stage 3)

Dietary Supplement: a formula with prebiotics and milk fat
Provided in a formula added with prebiotics and milk fat for 1 month

Outcome Measures

Primary Outcome Measures

  1. Change in stool bifidobacteria level [32 days]

    Stool sample analysis

Secondary Outcome Measures

  1. Change in stool lactobacillus level [32 days]

    Stool sample analysis

  2. Change in stool characteristics [32 days]

    • Stool image analysis based on the 4-point Brussels Infant and Toddler Stool Scale (watery, loose, formed, hard, with hard stools indicating worse outcome)

  3. Change in gastrointestinal tolerance [32 days]

    Parent reported questionnaire

  4. Satisfaction with the study product [32 days]

    Parent reported questionnaire

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A to 2 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • The gestational age was 37-42 weeks at birth;

  • Birth weight ≥2,500 g and ≤ 4,500 g;

  • Chinese nationality;

  • Weight and height are within normal range (i.e. WHO Child Growth Standards

  • 2SD);

  • No relocation across provinces/ cities in the past 1 year and no plans to relocate during the study period.

  • Breastfeeding reference: breastfeeding at the time of enrollment, and the mother intends to continue breastfeeding throughout the study period;

  • Intervention arm: formula feeding / habitual milk drinking (formula milk, milk and other dairy products) at the time of enrollment, and willing to change from the original milk powder / dairy product to the study formula, and consume it as instructed during the study period;

  • The child's parent(s) / guardian has access to a mobile phone on which the secure digital WeChat platform can be installed and used, connect to the network, take photographs and record defecation, and complete questionnaires during the study;

  • The child's parent(s) / guardian is of legal age of consent, has sufficient command of Chinese (Mandarin) language to complete the informed consent and other study documents, is willing and able to fulfill the requirements of the study.

  • The child's parent(s) / guardians can be contacted directly by telephone or WeChat;

Exclusion Criteria:
  • Neonatal asphyxia at birth;

  • Chronic infectious, metabolic, genetic illness or other disease including any condition that impacts feeding or may impact study outcomes;

  • Cognitive and developmental disorders;

  • Antibiotic usage up to 2 weeks before enrollment;

  • Ongoing antibiotic treatment;

  • Taking probiotic supplements or formula with probiotics up to 1 month before enrollment;

  • Participation in other clinical trials;

  • Parent(s)' / guardian's refusal to participate in the study;

  • Known or suspected allergy to cow milk, soy or fish

Contacts and Locations

Locations

Site City State Country Postal Code
1 Guangdong Province Maternal and Children Hospital Guangzhou Guangdong China
2 Henan Children's Hospital Zhengzhou Henan China
3 Tangdu Hospital, Air Force Medical University Xi'an Shanxi China
4 Chengdu Women's and Children's Central Hospital Chengdu Sichuan China
5 Ningbo Women and Children's Hospital Ningbo Zhejiang China
6 Beijing Children's Hospital, Capital Medical University Beijing China

Sponsors and Collaborators

  • Danone Nutricia
  • Nutricia Early Life Nutrition (Shanghai) Co., Ltd

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Danone Nutricia
ClinicalTrials.gov Identifier:
NCT04864665
Other Study ID Numbers:
  • SBB0E_34098
First Posted:
Apr 29, 2021
Last Update Posted:
Mar 23, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Danone Nutricia

Study Results

No Results Posted as of Mar 23, 2022